Amount of additional milestone payments.

No definition available.

Name:	casi_AdditionalMilestonePayments
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Accrued milestone payment under license agreement.

+ References

No definition available.

+ Details

Name:	casi_LicenseAgreementAccruedMilestonePayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contingent milestone payment under license agreement.

+ References

No definition available.

+ Details

Name:	casi_LicenseAgreementContingentMilestonePayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of milestone payment under license agreement.

+ References

No definition available.

+ Details

Name:	casi_LicenseAgreementMilestonePayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The additional period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	casi_NonRoyaltyExclusiveDistributionAdditionalPeriod
Namespace Prefix:	casi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	casi_NonRoyaltyExclusiveDistributionPeriod
Namespace Prefix:	casi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period considered for determination of supply costs in connection with the non-royalty exclusive distribution, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	casi_NonRoyaltyExclusiveDistributionSupplyCostDeterminationPeriodConsidered
Namespace Prefix:	casi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of installments for upfront payment.

+ References

No definition available.

+ Details

Name:	casi_NumberOfInstallmentsForUpfrontPayment
Namespace Prefix:	casi_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The potential milestone and royalty payment.

+ References

No definition available.

+ Details

Name:	casi_PotentialMilestonePaymentAndRoyalty
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of upfront payment.

+ References

No definition available.

+ Details

Name:	casi_UpfrontPayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

+ Details

Name:	us-gaap_MinorityInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
Namespace Prefix:	us-gaap_
Data Type:	enum2:enumerationSetItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_GuokangPharmaceuticalsCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BeijingTianshiTongdaPharmaceuticalsTechnologyCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_PharmathenGlobalBvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BlackBeltTherapeuticsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_CleaveTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_JuventasCellTherapyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BioinventInternationalAbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_ReimserPharmaGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Distribution Agreements (Details) ¥ in Millions		1 Months Ended											3 Months Ended				9 Months Ended		12 Months Ended
License and Distribution Agreements (Details) ¥ in Millions	Oct. 29, 2019	May 31, 2022 USD ($) installment	Aug. 31, 2021 USD ($)	Aug. 31, 2021 EUR (€)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Nov. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CNY (¥)	Apr. 30, 2019 USD ($)	Apr. 30, 2019 EUR (€)	Mar. 31, 2019	Sep. 30, 2022 USD ($)	Mar. 31, 2022	Sep. 30, 2021 USD ($)	Sep. 30, 2020 CNY (¥)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Sep. 30, 2022 CNY (¥)	Aug. 31, 2021 EUR (€)
License and Distribution Agreements
Research and Development Asset Acquired Other than through Business Combination, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]																			Acquired in-process research and development
Acquired in-process research and development													$ 0		$ 0		$ 0	$ 6,555,000
China Resources Guokang Pharmaceuticals Co., Ltd
License and Distribution Agreements
Non Royalty Exclusive Distribution Period												3 years
Non royalty exclusive distribution additional period														2 years
Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd
License and Distribution Agreements
Upfront payment		$ 10,000,000
Number of installments for upfront payment \| installment		2
Pharmathen Global BV
License and Distribution Agreements
Upfront payment \| €																						€ 1,000,000
Non Royalty Exclusive Distribution Period	10 years
Additional milestone payments paid																				$ 1,700,000	€ 1,500,000
Non-royalty exclusive distribution period at agreed cost	3 years
Pharmathen Global BV \| Maximum
License and Distribution Agreements
Additional milestone payments paid \| €																					€ 2,000,000
Black Belt Therapeutics Ltd
License and Distribution Agreements
Upfront payment										$ 5,700,000	€ 5,000,000											€ 5,000,000
Milestone payment			$ 305,000	€ 250,000	$ 750,000
Accrued milestone payment			$ 305,000																					€ 250,000
In-process research and development expensed																			$ 1,100,000
Potential milestones and royalties of up to										$ 46,300,000
Cleave Therapeutics, Inc
License and Distribution Agreements
Upfront payment						$ 5,500,000
Acquired in-process research and development																			$ 5,500,000
Cleave Therapeutics, Inc \| Maximum
License and Distribution Agreements
Milestone payment						$ 74,000,000
Juventas Cell Therapy Ltd.
License and Distribution Agreements
Milestone payment								$ 10,000,000	¥ 70.0							¥ 70.0
Equity attributable to noncontrolling interest													33,800,000				33,800,000						¥ 240.9
BioInvent International AB
License and Distribution Agreements
Upfront payment							$ 5,900,000
Acquired in-process research and development																				$ 5,900,000
BioInvent International AB \| Maximum
License and Distribution Agreements
Potential milestones and royalties of up to							$ 83,000,000
Riemser Pharma GmbH
License and Distribution Agreements
Contingent milestone payment													$ 0				$ 0